KRAS and acquired polycythemia vera: For example, TET2 mutations, when harboring FLT3-ITD mutation, induced AML (46); TET2 mutations, if combined with JAK2 and ASXL1 mutation, generated MPN, such as polycythemia vera (PV) and secondary myelofibrosis (MF) (47–50); finally, TET2 mutations, together with mutations in SRSF2 and KRAS, were associated with CMML (23) (Figure 4).